ENDPOINTS NEWS2h
As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket
AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...
ENDPOINTS NEWS20h
Re­vance and Crown are al­most ready to close their deal af­ter ear­li­er bid­ding war
Revance Therapeutics accepts Crown Laboratories' $3.65/share acquisition offer over rival bid from Teoxane, ending battle for ...